Headline
Oxford Biomedica cuts full-year revenue guidance on client ordering and Durham site delays; a rare downgrade in an otherwise steady UK tape.
What UK Plc said today
The clearest signal is a guidance cut from OXB: FY 2026 revenue now expected at £180-200m, reflecting "short-term impact of changes in client ordering behaviour and delayed operational readiness of Durham, NC site" — despite H1 revenue of £80m (+c.9% YoY) and "record new client activity" with 17 new clients signed. The tone is mixed rather than a full profit warning, but the guidance downgrade stands out on a day with none flagged in Tier A.
Elsewhere, trading updates were steadier. SDG delivered H1 FY27 revenue of £51.4m (+6% YoY) in line with expectations, with "double-digit growth in North America and Manufacturing" and management "particularly excited about our prospects in the US, where trading has been excellent." TGA issued new guidance ahead of consensus, with EPS expected between R10.75 and R11.10, flagging "a non-cash profit of R1.0 billion recognised on the sale of the Kleinkopje mining right."
Interim results from SRAD showed revenue down 9.1% to £124.0m on 14.6% organic volume declines, but adjusted operating profit rose 4.9% to £16.7m as margins expanded 1.8ppts to 13.5% and ROCE climbed to 29.0% — a textbook margin-over-volume story, with the interim dividend up 5% to 3.19p and full-year outlook "unchanged." TRIG reported NAV per share of 101.1p (down from 104.0p at end-2025), reaffirmed the 7.55p dividend target (c.10% yield), and signed a £155m disposal of its 17.5% Beatrice stake in July; management flagged AI-driven power demand as increasing "demand for secure and domestically generated electricity."
M&A activity centred on PHAR, where Ratio Petroleum's recommended increased offer values Pharos at ~£146.4m (32.8183p per share including a 4.0p special dividend), backed by a fresh letter of credit from Israel Discount Bank.
Statistical releases
- ONS Public service productivity, quarterly, UK: January to March 2026 — a key input into GDP quality and fiscal productivity debates.
- ONS Gross domestic expenditure on research and development, UK: 2024 — the annual read on total R&D intensity across business, government and higher education.
Policy / monetary
Nothing from the Bank of England. HMT announced a £100m commitment via the British Business Bank's Investor Pathways Capital Initiative to expand venture capital access "in every postcode" — modest in scale but consistent with the government's growth-agenda framing around early-stage funding.
Themes
- Margin discipline masking volume weakness. SRAD holds guidance and expands margins despite a 14.6% volume decline, exiting a loss-making German contract and cutting Turkish exposure. The playbook — trade volume for mix and cost — is the survival mode of UK industrials facing "continuation of cost inflation and ongoing weakness in our end markets."
- AI and energy demand crossing into infrastructure narrative. TRIG explicitly cites "the growing adoption of energy-intensive technologies, including AI" as a driver of UK/European power demand — a theme now migrating from tech into renewables and grid capital.
- Capital-return churn dominates the tape. 20 Tier C items but almost all sub-£3m issue/buyback administration — BFSP, BRAI, BRFI, HFEL, OIT, SMIF, TFIF etc. The single transformative item is the PHAR bid; the rest is housekeeping.
Watch
- CAML H1 2026 results and webcast 26 August 2026, 09:30 BST — today's notice was procedural.
- MSLH investor presentation 21 August 2026 covering sustainability and enterprise-excellence strategy.
- MNTN board additions of Graeme Proudfoot (1 September 2026) and Wendy Colquhoun (1 October 2026).
- RVRB capital reduction / Liontrust share distribution effective on or before 31 August 2026.
- PHAR/Ratio Petroleum Long Stop Date 15 July 2027; refinancing of the letter of credit to watch.